Propanc Biopharma's Lead Asset PRP Shows Promising Results in Pancreatic Cancer Models

Propanc Biopharma's lead asset, PRP, has shown over 85% tumor growth inhibition in preclinical pancreatic cancer models. The therapy targets cancer stem cells, blocks metastasis, and boosts chemosensitivity with minimal side effects. A Phase 1b trial is planned for 2026, backed by fresh funding and FDA Orphan Drug status for pancreatic cancer. Propanc aims to transform cancer care with its multi-targeted approach.